| Private Placement / Financing Transactions
Third Arc Bio: The company raised $217 million of Series A venture funding in a deal led by Cormorant Asset Management, Hillhouse Investment Group and Andreessen Horowitz on February 4, 2026, putting the company’s pre-money valuation at $97 million. AbbVie Ventures, Foresite Capital, Logos Capital, Freepoint Capital Group, Aberdeen Investments (Scotland), Alderline Group, Galapagos Capital, Goldman Sachs Asset Management, BVF Partners, T. Rowe Price Group, Janus Henderson Investors and Marshall Wace also participated in the round. The company is an operator of a biotech company intended to research multifunctional antibodies.
Angitia Biopharmaceuticals: The company raised $130 million of Series D venture funding in a deal led by Frazier Healthcare Partners and Venrock on February 5, 2026. Yonghua Capital, Bain Capital Life Sciences, OrbiMed, Hillhouse Investment Group, RA Capital Management, Ascenta Capital, TF Capital, Legend Capital, 3H Health Investment, Elikon Venture, Morningside Group, Janus Henderson Investors, BlackRock, BVF Partners, Logos Capital and Wellington Management also participated in the round. The company is a clinical-stage biotechnology company developing biologic therapies targeting endocrine and metabolic disease pathways.
Lotus Health AI: The company raised $35 million of Series A venture funding in a deal led by Kleiner Perkins, CRV and Andreessen Horowitz on February 3, 2026, putting the company’s pre-money valuation at $112 million. Sequoia Capital and other undisclosed investors also participated in the round. The company is a developer of advanced healthcare analytics technology designed to improve patient outcomes through data-driven information.
Xandar Kardian: The company is in the process of raising $25 million of Series B venture funding as of February 5, 2026. The company is a developer of a radar-based sensing platform designed to monitor human presence, motion, and vital signs for security, cleantech, and healthcare use.
ALTx Therapeutics: The company raised EUR 12.5 million of venture funding from Syncona, Cancer Research Horizons and The Francis Crick Institute on February 5, 2026. The company is a developer of oncology therapeutics intended to support the treatment of cancers associated with the alternative lengthening of telomeres pathway.
Apmonia Therapeutics: The company raised EUR 10 million of venture funding from Capital Cell, Capital Grand Est and Fournier-Majoie Foundation on February 3, 2026. Finovam Gestion and Angels Santé also participated in the round. The company is a developer of peptide-based biotechnology designed to provide therapeutic strategies for multiple types of cancer.
Nature’s Toolbox: The company raised $10.3 million of Series C venture funding from undisclosed investors on February 4, 2026, putting the company’s pre-money valuation at $60.6 million. The company is a developer of biomanufacturing platforms that use engineered microbial systems to produce therapeutic proteins and biologics.
AngioWave Imaging: The company is in the process of raising $10 million of Series B venture funding on February 4, 2026. The company is a developer of AI-based post-processing software used to enhance vascular visualization during angiographic imaging procedures.
SOMAVAC: The company is in the process of raising an estimated $10 million of venture funding in the form of convertible debt as of February 4, 2026. The company is a developer of wearable medical devices that apply a sustained vacuum to reduce post-surgical fluid accumulation.
Stratus Medical: The company raised $10 million of Series B venture funding in a deal led by Wasatch Health on February 4, 2026. Other undisclosed investors also participated in the round. The company is a developer of medical devices designed to offer advanced radiofrequency ablation treatment for chronic pain.
Dionymer: The company raised EUR 7 million of venture funding from UI Investissement, BNP Paribas Développement and M Capital Partners on February 2, 2026. Bpifrance also participated in the round. The company is a developer of a biotechnology platform designed to transform biowaste into circular and biodegradable polymer materials that can replace conventional petrochemical plastics.
XDemics: The company raised $7.4 million of venture funding from undisclosed investors on February 6, 2026. The company is a biotechnology research firm engaged in therapeutic discovery and preclinical development in Novato, California.
NuVision Biotherapies: The company raised GBP 4.8 million of venture funding in a deal led by Mercia Ventures on February 5, 2026, putting the company’s pre-money valuation at GBP 4.83 million. Newable Partnership, Pioneer Group and University of Nottingham also participated in the round. The company is a developer of ophthalmic therapy products designed to offer surgeons innovative new therapies for ocular care.
Sonovascular: The company raised an additional $6 million of Series A venture funding in a deal led by Harbright Ventures on February 3, 2026, putting the company’s pre-money valuation at an estimated $19 million. The company is a developer of a multi-mechanistic ultrasound-facilitated thrombectomy system designed for the treatment of arterial and venous thrombosis.
Cognixion: The company raised $4 million of venture funding in the form of convertible debt from undisclosed investors on February 2, 2026. The company is a developer of neurotechnology systems that use brain-computer interface hardware and software to translate neural signals into speech or device control.
Agiga: The company raised $3.6 million of venture funding in the form of options and warrants from undisclosed investors on February 4, 2026. The company is a developer of a wearable artificial intelligence system designed to assist people with visual impairments in navigating their environment.
Imbed Biosciences: The company raised an undisclosed amount of venture funding from BioLab Holdings on February 4, 2026. The company is a developer of advanced wound care devices incorporating antimicrobial and bioresorbable materials to support tissue healing.
|
